8-K - Orchestra BioMed Holdings, Inc. | StockGist

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. On August 1, 2025, Orchestra BioMed Holdings, Inc. (the “ Company ”) entered into an underwriting agreement (the “

Material Agreement

$2.75$2.75$40.0M

7.01

of this Current Report, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, r

Regulation Fd

8.01

. Other Events. As previously announced, on July 31, 2025, the Company entered into Stock Purchase Agreements with Ligand Pharmaceuticals Incorporated (“ Ligand

Other Event

$16.2M$3.67

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement, dated as of August 1, 2025, by and among Orchestra Bio

Exhibits Only

Source Document

Exhibits (6)

1.1

EXHIBIT 1.1

4.1

EXHIBIT 4.1

5.1

EXHIBIT 5.1

8-K

FORM 8-K

99.1

EXHIBIT 99.1

99.2

EXHIBIT 99.2